Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Medicxi
Medicxi
Activities:
Finance
Pharmaceutical
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Manufacturing
Lilly set to acquire Versanis Bio to "improve patient outcomes in cardiometabolic diseases"
Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash
Research & Development
Sosei Heptares announces €40 million Medicxi investment
Two asset-centric companies have been formed to develop Sosei’s novel therapies for neurological diseases funded by Medicxi
Research & Development
Moncef Slaoui joins Medicxi
Research & Development
Medicxi launches first $300m late-stage life sciences fund: Medicxi Growth 1
Novartis’ backing adds further validation to the Medicxi investment strategy
Subscribe now